Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis-Reference-Cited by-同舟云学术

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis

Published:2017-03-31 Issue:8 Volume:143 Page:1585-1596
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Giles Francis J.,Rea Delphine,Rosti Gianantonio,Cross Nicholas C. P.,Steegmann Juan Luis,Griskevicius Laimonas,le Coutre Philipp,Coriu Daniel,Petrov Ljubomir,Ossenkoppele Gert J.,Mahon Francois-Xavier,Saussele Susanne,Hellmann Andrzej,Koskenvesa Perttu,Brümmendorf Tim H.,Gastl Gunther,Castagnetti Fausto,Vincenzi Beatrice,Haenig Jens,Hochhaus Andreas

Funder

Novartis Pharma AG

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/article/10.1007/s00432-017-2402-x/fulltext.html

Reference32 articles.

1. Berger U et al (2003) Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha. Leukemia 17:1820–1826. doi: 10.1038/sj.leu.2403042

2. Breccia M, Tiribelli M, Alimena G (2012) Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data. Crit Rev Oncol Hematol 84:93–100. doi: 10.1016/j.critrevonc.2012.01.001

3. Castagnetti F et al (2015) Differences among young adults, adults and elderly chronic myeloid leukemia patients. Ann Oncol 26:185–192. doi: 10.1093/annonc/mdu490